Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 – 2010)

Bibliography

• De Clercq E. New approaches toward anti-HIV chemotherapy. J Med Chem 2005;48:1297-313
   PubMed Web of Science ®Google Scholar
• Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005;11:1805-43
   PubMed Web of Science ®Google Scholar
• Agrawal L, Lu X, Jin Q, Alkhatib G. Anti-HIV therapy: current and future directions. Curr Pharm Des 2006;12:2031-55
   PubMed Web of Science ®Google Scholar
• Tronchet JM, Seman M. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: from the biology of reverse transcription to molecular design. Curr Top Med Chem 2003;3:1496-511
   PubMed Web of Science ®Google Scholar
• Martins S, Ramos MJ, Fernandes PA. The current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infection. Curr Med Chem 2008;15:1083-95
   PubMed Web of Science ®Google Scholar
• Sweeney ZK, Klumpp K. Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data. Curr Opin Drug Discov Devel 2008;11:458-70
   PubMedGoogle Scholar
• Zhou Z, Lin X, Madura JD. HIV-1 RT nonnucleoside inhibitors and their interaction with RT for antiviral drug development. Infect Disord Drug Targets 2006;6:391-413
   PubMedGoogle Scholar
• Seminari E, Castagna A, Lazzarin A. Etravirine for the treatment of HIV infection. Expert Rev Anti Infect Ther 2008;6:427-33
   PubMed Web of Science ®Google Scholar
• Daar ES. Emerging resistance profiles of newly approved antiretroviral drugs. Top HIV Med 2008;16:110-16
   PubMedGoogle Scholar
• Arendt G, de Nocker D, von Giesen HJ, Nolting T. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf 2007;6:147-54
   PubMed Web of Science ®Google Scholar
• Fumaz CR, Munoz-Moreno JA, Molto J, Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 2005;38:560-5
   PubMed Web of Science ®Google Scholar
• SUSTIVA® (efavirenz) capsules and tablets: Package insert, Bristol-Myers Squibb Co., Princeton, NJ, USA (2008). Package inserts. Available from: Bms/com/pi/pi_sustiva.pdf
   Google Scholar
• Boone LR. Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr Opin Investig Drugs 2006;7:128-35
   PubMedGoogle Scholar
• Zhan P, Liu X, Fang Z, Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur J Med Chem 2009;44:4648-53
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X, Fang Z, 1,2,3-Selenadiazole thioacetanilides: synthesis and anti-HIV activity evaluation. Bioorg Med Chem 2009;17:6374-9
   PubMedGoogle Scholar
• Zhan P, Liu X, Li Z, Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: synthesis and preliminary SAR studies. Bioorg Med Chem 2009;17:5920-7
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X, Zhu J, Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem 2009;17:5775-81
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X, Cao Y, 1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem Lett 2008;18:5368-71
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X, Li Z, 1,2,3-Thiadiazole thioacetanilides. Part 2: synthesis and biological evaluation of a new series of 2-{[4-(3,4-dichlorophenyl)-1,2,3- thiadiazol-5-yl]sulfanyl}acetanilides as HIV-1 inhibitors. Chem Biodivers 2010;7:1717-27
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu H, Liu X, Synthesis and anti-HIV activity evaluation of novel N′-arylidene-2-[1- (naphthalen-1-yl)-1H-tetrazol-5-ylthio] acetohy drazides. Med Chem Res 2009;19:652-63
   Web of Science ®Google Scholar
• Liu X, Zhan P, Pannecouque C, De Clercq E. Design, synthesis and anti-HIV-1 evaluation of novel arylazolylthioacetanilides as potent NNRTIS. Antiviral Res 2009;82:A44-5
   Web of Science ®Google Scholar
• Liu XY, Yan RZ, Wang Y, Synthesis and anti-HIV activity evaluation of novel 2,4-disubstituted 7-methyl-1,1,3-trioxo-2,4-dihydro-pyrazolo-[4,5-e][1,2] thiadiazines. Arch Pharm (Weinheim) 2008;341:216-22
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X, De Clercq E. Recent advances in antiviral activity of benzo/heterothiadiazine dioxide derivatives. Curr Med Chem 2008;15:1529-40
   PubMed Web of Science ®Google Scholar
• Sluis-Cremer N, Tachedjian G. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res 2008;134:147-56
   PubMed Web of Science ®Google Scholar
• Alcaro S, Artese A, Ceccherini-Silberstein F, Computational analysis of Human Immunodeficiency Virus (HIV) Type-1 reverse transcriptase crystallographic models based on significant conserved residues found in Highly Active Antiretroviral Therapy (HAART)-treated patients. Curr Med Chem 2010;17:290-308
   PubMed Web of Science ®Google Scholar
• Prajapati DG, Ramajayam R, Yadav MR, Giridhar R. The search for potent, small molecule NNRTIs: a review. Bioorg Med Chem 2009;17:5744-62
   PubMed Web of Science ®Google Scholar
• Maddocks S, Dwyer D. The role of non-nucleoside reverse transcriptase inhibitors in children with HIV-1 infection. Paediatr Drugs 2001;3:681-702
   PubMedGoogle Scholar
• de Bethune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009). Antiviral Res 2010;85:75-90
   PubMed Web of Science ®Google Scholar
• Waters L, John L, Nelson M. Non-nucleoside reverse transcriptase inhibitors: a review. Int J Clin Pract 2007;61:105-18
   PubMed Web of Science ®Google Scholar
• De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. Chem Biodivers 2004;1:44-64
   PubMed Web of Science ®Google Scholar
• De Clercq E. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Farmaco 1999;54:26-45
   PubMedGoogle Scholar
• Zhan P, Liu X, Li Z. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006–2008 update. Curr Med Chem 2009;16:2876-89
   PubMed Web of Science ®Google Scholar
• Chen X, Zhan P, Li D, Recent advances in DAPYs and related analogues as HIV-1 NNRTIs. Curr Med Chem 2011;18:359-76
   PubMed Web of Science ®Google Scholar
• Medina-Franco JL, Martinez-Mayorga K, Juarez-Gordiano C, Castillo R. Pyridin-2(1H)-ones: a promising class of HIV-1 non-nucleoside reverse transcriptase inhibitors. ChemMedChem 2007;2:1141-7
   PubMed Web of Science ®Google Scholar
• Zhan P, Li Z, Liu X, De Clercq E. Sulfanyltriazole/tetrazoles: a promising class of HIV-1 NNRTIs. Mini Rev Med Chem 2009;9:1014-23
   PubMed Web of Science ®Google Scholar
• Das K, Lewi PJ, Hughes SH, Arnold E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol 2005;88:209-31
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X, Li Z, Design strategies of novel NNRTIs to overcome drug resistance. Curr Med Chem 2009;16:3903-17
   PubMed Web of Science ®Google Scholar
• Guo H, Kim CU, Kim HS, Preparation of pyrimidinediones as HIV reverse transcriptase inhibitors. WO2008016522; 2008 (Gilead Sciences, Inc., USA; Korea Research Institute of Chemical Technology)
   Google Scholar
• Andrews CW III, Cao P, Freeman GA, Preparation of dihydropyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors for treating HIV infection. WO2009020457; 2009
   Google Scholar
• He G, Kim CU, Mitchell ML, Xu L. Novel HIV reverse transcriptase inhibitors. WO2009005693; 2009
   Google Scholar
• Le VK, Georges B, Hevesi L, Preparation of 2-pyridinone derivatives having HIV inhibiting properties. EP1516873; 2005
   Google Scholar
• Kim C, Mitchell ML, Son JC. Pyridone derivatives as non-nucleoside reverse transcriptase inhibitors. WO2010009047; 2010
   Google Scholar
• Le VK, Georges B, Hevesi L, 2-Pyridinone derivatives, having HIV inhibiting properties. WO2005028442; 2005
   Google Scholar
• Le VK, Georges B, Hevesi L, 2-Pyridinone derivatives, having HIV inhibiting properties. US2007275953; 2007
   Google Scholar
• Guillemont JEG, Heeres J, Lewi PJ. Preparation of HIV-inhibiting 5-substituted pyrimidines. WO2006035069; 2006 (Tibotec Pharmaceuticals Ltd, Ire.)
   Google Scholar
• Guillemont JEG, Mordant CI. Preparation of HIV inhibiting 5,6-substituted pyrimidines. WO2008080964; 2008 (Tibotec Pharmaceuticals Ltd, Ire.)
   Google Scholar
• Guillemont JEG, Mordant CI, Schmitt BA. Preparation of HIV inhibiting 5,6-substituted pyrimidines. WO2008080965; 2008 (Tibotec Pharmaceuticals Ltd, Ire.)
   Google Scholar
• Brotherton-Pleiss CE, Kertesz DJ, Yang M. Preparation of piperidinylaminopyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors. WO2008071587; 2008
   Google Scholar
• Kestesz DJ, Brotherton-Pleiss C. Non-nucleoside reverse transcriptase inhibitors. US2008146595; 2008
   Google Scholar
• Guillemont J, Emile G. HIV inhibiting 5-amido substituted pyrimidines. US20100168104; 2010
   Google Scholar
• De Kock, Herman Augustinus; Wigerinck, Piet Piet Tom Bert Paul. Preparation of HIV inhibiting 2-(4-cyanophenyl)-6-hydroxylaminopyrimidines. WO2006094930; 2006 (Tibotec Pharmaceuticals Ltd, Ire.)
   Google Scholar
• Chen F, Xiong Y. Preparation of diaryl-triazine derivatives for treatment of AIDS. CN101265237; 2008
   Google Scholar
• Rodgers J, Wang H. 2, 4-Disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors. US6809109; 2004
   Google Scholar
• Xie L, Tian X, Li G. The 2-(4-substituted phenylamino) polysubstituted pyridine compounds as the inhibitors of non-nucleoside HIV reverse transcriptase, praparation methods and uses thereof. WO2010040275; 2010
   Google Scholar
• Xie L, Tian X, Li G. Pyridine derivatives as HIV revertase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of HIV infections. CN101717364; 2010
   Google Scholar
• Xie L, Qin B, Lee K-H, Substituted diphenylamines as inhibitors of reverse transcriptase, process of preparing them and use thereof. WO2009049491; 2009
   Google Scholar
• Guillemont JEG, Paugam M, Delest BFM, HIV inhibiting bicyclic pyrimidine derivatives. WO2006045828; 2006
   Google Scholar
• Girardet JL, Koh Y-H, Shaw S, Kin HW. Preparation of purines, azapurines, and deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV infection. WO2006122003; 2006
   Google Scholar
• Girardet JL, Koh Y-H, Shaw S, Kim HW. Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of HIV. US20090124802; 2009
   Google Scholar
• Girardet J-L, Hong Z, Shaw S, Koh Y-H. Cyanophenylamino-substituted thienopyrimidine compounds as non-nucleoside reverse transcriptase inhibitors, their preparation, pharmaceutical compositions, and use as anti-HIV treatment. WO2008058285; 2008 (Ardea Biosciences, Inc., USA)
   Google Scholar
• Jorgensen WL. Novel azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) in antiviral therapy(HIV). WO2009005811; 2009
   Google Scholar
• Jorgensen WL. Novel azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) in antiviral therapy (HIV). US20100168190; 2010
   Google Scholar
• Nitz TJ, Salzwedel K, Finnegan C, Anti-HIV compounds. WO2009085256; 2009
   Google Scholar
• Jorgensen WL, Ruiz-Caro J, Hamilton AD. Compounds and methods for the treatment of viruses and cancer. WO2007038387; 2007
   Google Scholar
• Jones LH, Middleton DS, Mowbray CE, Preparation of phenoxyphenoxyacetamides and related compounds as inhibitors of HIV-1 reverse transcriptase. WO2006067587; 2006 (Pfizer Ltd, UK)
   Google Scholar
• Peat AJ, Sebahar PR, Youngman M, Chemical compounds. WO2008154271; 2008
   Google Scholar
• Saggar SA, Sisko JT, Tucker TJ, HIV reverse transcriptase inhibitors. US20070021442; 2007
   Google Scholar
• Mirzadegan T, Silva T. N-phenyl-phenylacetamide derivatives as non-nucleoside reverse transcriptase inhibitors, their preparation, pharmaceutical compositions, and use in therapy. US2007088053; 2007 (Roche Palo Alto LLC, USA)
   Google Scholar
• Silva T, Sweeney ZK. N-phenyl-phenylacetamide derivatives as non-nucleoside reverse transcriptase inhibitors, their preparation, pharmaceutical compositions, and use in therapy. US2007088015; 2007
   Google Scholar
• Silva T, Sweeney ZK. N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors. WO2007045572; 2007 (Roche Palo Alto LLC, USA)
   Google Scholar
• Dunn JP, Hirschfeld DR, Silva T, Preparation of phenoxyphenylacetamides as non-nucleoside reverse transcriptase inhibitors. US2005239881; 2005
   Google Scholar
• Dunn JP, Hirschfeld DR. Use of phenylacetamides as non-nucleoside reverse transcriptase inhibitors for treating retroviral infections. US2005239880; 2005
   Google Scholar
• Dunn JP, Hirschfeld DR, Silva T, Non-nucleoside reverse transcriptase inhibitors. WO2005102989; 2005. (Roche Palo Alto LLC, USA)
   Google Scholar
• Sweeney ZK. Preparation of 2-(3-phenoxyphenoxy)-N-phenyl-acetamide derivatives for treatment of AIDS. WO2008009613; 2008
   Google Scholar
• Peat AJ, Sebahar PR, Youngman M, Preparation of N-(cyanophenoxybenzyl) (hetero)aryl carboxamides as a non-nucleoside reverse transcriptase inhibitors for treating HIV infection. WO2008154271; 2008
   Google Scholar
• Wu B, Nguyen TN, Ellis DA, Preparation of phenoxyphenylpyrrolidones for treatment of HIV infection. WO2006081554; 2006
   Google Scholar
• Dunn JP, Elworthy TR, Hogg JH, Stefanidis D. Preparation of benzyl pyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors. WO2005090317; 2005
   Google Scholar
• Dunn JP, Dymock BW, Mirzadegan T, Non-nucleoside reverse transcriptase inhibitors. US20040198736; 2004
   Google Scholar
• Kennedy-Smith J, Sweeney ZK, Wu J. Diazacyclic derivatives as non-nucleoside reverse transcriptase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of HIV infection. WO2008145562, 2008
   Google Scholar
• Kennedy-Smith J, Sweeney ZK, Wu J. Non-nucleoside reverse transcriptase inhibitors. US2009076045; 2009
   Google Scholar
• Saito YD, Smith M, Sweeney ZK. Preparation of heterocyclic non-nucleoside reverse transcriptase inhibitors. US2007078128; 2007 (Roche Palo Alto LLC, USA)
   Google Scholar
• Dunn JP, Elworthy TR, Stefanidis D, Sweeney ZK. Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors, their preparation, pharmaceutical compositions, and use in therapy. WO2006010545; 2006 (F. Hoffmann-La Roche AG, Switz.)
   Google Scholar
• Sweeney ZK, Welch M. Substituted [1,2,4]-triazoles as non-nucleoside reverse transcriptase inhibitors and their preparation and use for prevention and treatment of HIV-1 infections. WO2008119662; 2008 (F. Hoffmann-La Roche A.-G., Switz.)
   Google Scholar
• Martin M, Vora HU. Heterocyclic reverse transcriptase inhibitors. US20060223874; 2006
   Google Scholar
• Martin M, Vora H. Preparation of 1,2,4-triazole-5-ones as reverse transcriptase inhibitors for treatment of AIDS or ARC. WO2006099978; 2006 (F.Hoffmann-La Roche A.-G., Switz.)
   Google Scholar
• Dunn JP, Swallow S, Sweeney ZK, Nonnucleoside reverse transcriptase inhibitors. US20070179157; 2007
   Google Scholar
• Aquino CJ, Dickson H, Peat AJ. Preparation of 1,3,4-oxadiazoles as a non-nucleoside reverse transcriptase inhibitor for treating human immunodeficiency virus infection. WO2008157330; 2008 (SmithKline Beecham Corp., USA)
   Google Scholar
• Aquino CJ, Dickson H. Chemical compounds. WO2008157273; 2008
   Google Scholar
• Billedeau RJ, Palmer WS, Sweeney ZK, Wu J. Preparation of pyridazine derivatives as non-nucleoside reverse transcriptase inhibitors. WO2008122534; 2008 (F. Hoffmann-La Roche A.-G., Switz.)
   Google Scholar
• Billedeau RJ, Palmer W, Sweeney ZK, Wu J. Non-nucleoside reverse transcriptase inhibitors. US2008293664; 2008
   Google Scholar
• Billedeau RJ, Sweeney ZK. Heterocyclic antiviral compounds. WO2009080534; 2009
   Google Scholar
• Billedeau RJ, Sweeney ZK. Heterocyclic antiviral compounds. US2009170856; 2009
   Google Scholar
• Elworthy TR, Hogg JH, Kennedy-Smith J, Preparation of urea and carbamate derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors. WO2009000663; 2009
   Google Scholar
• Elworthy TR, Hogg JH, Kennedy-Smith J, Non-nucleoside reverse transcriptase inhibitors. US2009012034; 2009 (F. Hoffmann-La Roche A.-G., Switz.)
   Google Scholar
• Kennedy-Smith J, Palmer WS, Sweeney ZK. Preparation of phenoxybenzene derivatives as non-nucleoside reverse transcriptase inhibitors. WO2008019968; 2008 (F. Hoffmann-La Roche AG, Switz.)
   Google Scholar
• Saggar SA, Sisko JT, Tucker TJ, Preparation of heterocyclic phenoxy compounds as HIV reverse transcriptase inhibitors. US2007021442; 2007 (Merck & Co., Inc., USA)
   Google Scholar
• Anthony NJ, Gomez R, Jolly SM. 1-(1H-Pyrazolo[3,4-b]pyridin-3-ylmethyl)-1H-indazole derivatives as non-nucleoside reverse transcriptase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of HIV infection. WO2008076223; 2008 (Merck & Co., Inc., USA)
   Google Scholar
• Anthony NJ, Gomez R, Jolly SM, Preparation of substituted indazoles, benzotriazoles and related bicyclic compounds as non-nucleoside reverse transcriptase inhibitors. WO2008076225; 2008 (Merck & Co., Inc., USA)
   Google Scholar
• Anthony NJ, Gomez R, Jolly SM, Non-nucleoside reverse transcriptase inhibitors. US2008275097; 2008
   Google Scholar
• Tucker TJ, Tynebor R, Sisko JT, Non-nucleoside reverse transcriptase inhibitors. WO2009067166; 2009
   Google Scholar
• Arora N, Billedeau RJ, Kennedy-Smith J, Pyridine derivatives as inhibitors of HIV-1 reverse transcriptase. WO2010026075; 2010
   Google Scholar
• Arora N, Billedeau RJ, Kennedy-Smith J, Inhibitors of HIV-1 reverse transcriptase. US2010056535; 2010
   Google Scholar
• Andrews CW III, Chan JH, Freeman GA, Benzophenones as inhibitors of reverse transcriptase. US7273863; 2007
   Google Scholar
• Bonneau P, Deroy P, Gagnon A, Preparation of phenylalkyne derivatives as non nucleoside reverse transcriptase inhibitors for treatment of HIV infection. US2006069261; 2006 (Boehringer Ingelheim International GmbH, Germany)
   Google Scholar
• Simoneau B, O'Meara J, Yoakim C. Preparation of acylaminobenzoic acid derivatives as non-nucleoside reverse transcriptase inhibitors. US2006025480; 2006 (Boehringer Ingelheim International G.m.b.H., Germany)
   Google Scholar
• Aquino CJ, Freeman GA, Martin MT. Preparation of 2-({4-chloro-2-[(3-chloro-5-cyanophenyl)carbonyl]phenyl}oxy)-N-(4-{[(2S)-2,3-dihydroxy-3-methylbutyl}oxy}-2-methylphenyl}acetamide as a non-nucleoside reverse transcriptase inhibitor. WO2007121415; 2007
   Google Scholar
• Aquino CJ, Freeman GA, Martin MT. Preparation of 2-({4-chloro-2-[(3-chloro-5-cyanophenyl)carbonyl]phenyl}oxy)-N-{3-fluoro-4-[(2-hydroxy-2-methylpropyl)oxy]-2-methylphenyl}acetamide as a non-nucleoside reverse transcriptase inhibitor. WO2007121418; 2007
   Google Scholar
• Aquino CJ, Freeman GA, Martin MT. Preparation of 2-({4-chloro-2-[(3-chloro-5-cyanophenyl)carbonyl]phenyl}oxy)-N-{4-[(2,3-dihydroxy-3-methylbutyl)oxy]-3-fluoro-2-methylphenyl}acetamide as a non-nucleoside reverse transcriptase inhibitor. WO2007121416; 2007 (Smithkline Beecham Corp., USA)
   Google Scholar
• Girardet J-L, Zhang Z, Hamatake R, Non-nucleoside reverse transcriptase inhibitors. WO2004030611; 2004
   Google Scholar
• Simoneau B, Thavonekham B, Landry S, Non-nucleoside reverse transcriptase inhibitors. WO2004050643; 2004
   Google Scholar
• Simoneau B, Faucher A-M, Landry S, Non-nucleoside reverse transcriptase inhibitors. US2005054639; 2005
   Google Scholar
• Deroy P, Faucher A-M, Gagnon A, Non-nucleoside reverse transcriptase inhibitors. US20090143370, 2009
   Google Scholar
• Deroy P, Faucher A-M, Gagnon A, Preparation of acetamide derivatives as reverse transcriptase inhibitors for treatment of HIV. (Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma Gmbh & Co. KG). WO2005118575; 2005
   Google Scholar
• Shaw-Reid CA, Miller MD, Hazuda DJ, Preparation of tetrazolyl derivatives as HIV reverse transcriptase inhibitors. WO2005115147; 2005 (Merck & Co., Inc., USA; Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.)
   Google Scholar
• Girardet J-L, Koh Y-H, De la Rosa M, Preparation of S-triazolyl alpha-mercaptoacetanilides as inhibitors of HIV reverse transcriptase. WO2006026356; 2006 (Valeant Research & Development, USA)
   Google Scholar
• Girardet J-L, Koh Y-H, De la Rosa M, S-Triazolyl alpha-mercaptoacetanilides as inhibitors of HIV reverse transcriptase. US20080176850, 2008
   Google Scholar
• Girardet J-L, Koh Y-H. 2-(5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid and methyl ester. US20100081827; 2010
   Google Scholar
• Girardet J-L, Koh Y-H, De la Rosa M, N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl] -p-amino benzoic acids as HIV reverse transcriptase inhibitors. US20100137590; 2010
   Google Scholar
• Girardet J-L, Koh Y-H, De la Rosa M, N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl] -p-amino benzoic acids as HIV reverse transcriptase inhibitors. US20080319201; 2008
   Google Scholar
• Girardet J-L, Koh Y-H, De la Rosa M, Preparation of S-triazolyl alpha-mercaptoacetanilides as inhibitors of HIV reverse transcriptase. US2006270725; 2006 (Valeant Research & Development, USA)
   Google Scholar
• Koch U, Kinzel O, Muraglia E, Summa V. Preparation of N-Ph dicarbamate derivatives as HIV reverse transcriptase inhibitors. WO2006037468; 2006 (Istituto di Ricerche di Biologia Molecolare P Angeletti S.p.A., Italy)
   Google Scholar
• Olson MW, Di Grandi M, Prashad A. Carbamates as HIV anti-viral agents. US2005203176; 2005 (Wyeth, John, and Brother Ltd, USA)
   Google Scholar
• Su D-S, Anthony NJ, Lim JJ, Preparation of tetrahydroquinolines and related compounds as reverse transcriptase inhibitors. WO2007146230; 2007 (Merck & Co., Inc., USA)
   Google Scholar
• Antonov D, Sund C, Lindstroem S, Sahlberg C. Preparation of pyridinyl(thio)urea derivatives of cyclopropachromenes, cyclopropaindenes, cyclopropanaphthalenes, and benzocyclopropacycloheptenes as non-nucleoside reverse transcriptase inhibitors. WO2004021969; 2004 (Medivir Ab, Sweden)
   Google Scholar
• Sund C, Roue N, Lindstroem S, Non-nucleotide reverse transcriptase inhibitors. WO2005066131; 2005
   Google Scholar
• Williams TM, Zhang X-F. Preparation of indolecarboxylates and -carboxamides as HIV reverse transcriptase inhibitors. WO2007021629; 2007 (Merck & Co., Inc., USA)
   Google Scholar
• Williams TM, Zhang X-F. Non-nucleoside reverse transcriptase inhibitors. US2009131494; 2009
   Google Scholar
• Wolkenberg SE, Zhao Z, Lindsley CW. Preparation of indolesulfonamides as non-nucleoside HIV reverse transcriptase inhibitors for the treatment of HIV infection and AIDS. WO2007002368; 2007 (Merck & Co., Inc., USA)
   Google Scholar
• Lindsley CW, Leister WH, Wolkenberg SE. Preparation of sulfonylindoles as non-nucleoside HIV reverse transcriptase inhibitors for the treatment of HIV infection and AIDS. WO2007002481; 2007 & US20100179122; 2010 (Merck & Co., Inc., USA)
   Google Scholar
• Wolkenberg SE, Lindsley CW, Zhao Z, Williams TM. Preparation of indole derivatives as non-nucleoside reverse transcriptase inhibitors. WO2007002458; 2007 & US20100168097; 2007 (Merck & Co., Inc., USA)
   Google Scholar
• Storer R, Alexandre F-R, Dousson C, Enantiomerically pure phosphoindoles as HIV inhibitors. WO2008042240; 2008
   Google Scholar
• Storer R, Dousson C, Alexandre F-R, Roland A. Preparation of phospho-indoles as HIV inhibitors. US2006074054; 2006 (Idenix Pharmaceuticals, Inc., USA)
   Google Scholar
• Yoakim C, O'Meara J, Simoneau B, Preparation of 9H-imidazo[1,2-d]dipyrido[2,3-b: 3′,2′-f][1,4]diazepine derivatives as tetracyclic non-nucleoside reverse transcriptase inhibitors useful against wild type and double-mutation K103N/Y181C enzymes. WO2004026875; 2004 (Boehringer Ingelheim (Canada) Ltd, Canada)
   Google Scholar
• Gant TG, Sarshar S. Preparation of deuterium-incorporated cyclopropyldipyridodiazepinone derivatives for use as non-nucleoside reverse transcriptase inhibitors. WO2008103899; 2008 (Auspex Pharmaceuticals, Inc., USA)
   Google Scholar
• Meyer O, Heddesheimer I, Zerban G. Process for preparation of diazepine N-oxide derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors. WO2006048425; 2006 (Boehringer Ingelheim Pharma Gmbh & Co. KG, Germany)
   Google Scholar
• Jones LH, Newman SD, Swain NA. Preparation of 3-chloro-5-cyano thiophenyl substituted imidazole derivatives as HIV-1 reverse transcriptase inhibitors and modulators. WO2006072833; 2006 (Pfizer Ltd, UK)
   Google Scholar
• Jones LH, Mohammed S, Mowbray CE, Sulfur-linked imidazole compounds for the treatment of HIV. WO2005100322; 2005 (Pfizer Ltd, UK; Pfizer, Inc.)
   Google Scholar
• Jones LH, Mowbray CE, Price DA, Pyrazole derivatives. US2005004129; 2005
   Google Scholar
• Cushman MS, Sakamoto T, Cullen MD. Alkenyldiarylmethanes having nitrogen-containing carboxylic acid derivatives as non-nucleoside inhibitors of HIV-I reverse transcriptase. WO2008119028; 2008
   Google Scholar
• Cushman MS, Deng B-L. Preparation of alkenyldiarylmethanes and fused analogs as inhibitors of HIV-I reverse transcriptase. WO2007005531; 2007
   Google Scholar
• Cushman MS, Deng B-L. Alkenyldiarylmethanes, fused analogs and syntheses thereof. US2008300288; 2008
   Google Scholar
• Williams TM, Zhang X-F, Obligado VE, Poehnelt RA. Preparation of pyrrole carboxamides as non-nucleoside reverse transcriptase inhibitors. PCT Int Appl 2008:109. CODEN:PIXXD2 WO2008054605 A2
   Google Scholar
• Williams TM, Zhang X-F, Obligado VE, Poehnelt RA. Non-nucleoside reverse transcriptase inhibitors. US20100113421; 2010 (Merck & Co., Inc., USA)
   Google Scholar
• Olson M, Di GM. Preparation of triazole derivatives for treating HIV infections. US2005209287; 2005
   Google Scholar
• Botta M, Corelli F, Petricci E, Preparation of pyrimidine and pyrimidinone derivatives and their use for the treatment of HIV infections. WO2007043094; 2007
   Google Scholar
• Kesteleyn BRR, Van De Vreken W, Surleraux DLNG, Preparation of benzo[4,5]furo[3,2-b]pyridin-2-ones and pyrido[3,2-b]indol-2-ones as inhibitors of HIV reverse transcriptase. WO2005111044; 2005 (Tibotec Pharmaceuticals Ltd, Ire.)
   Google Scholar
• Kesteleyn BRR, Raboisson PJ-MB, Surleraux DLNG, Preparation of 1-heterocyclyl-1,5-dihydropyrido[3,2-b]indol-2-ones and analogs as antiviral agents. WO2005111047; 2005 (Tibotec Pharmaceuticals Ltd, Ire.)
   Google Scholar
• Kesteleyn BRR, Vendeville SMH, Kindermans NMF, Preparation of 1-phenyl-1,5-dihydropyrido[3,2-b]indol-2-ones and analogs as antiviral agents. WO2005111035; 2005 (Tibotec Pharmaceuticals Ltd, Ire.)
   Google Scholar
• Kesteleyn BRR, Vendeville SMH, Kindermans NMF, Preparation of substituted pyrido[3,2-b]indoles for use in pharmaceutical compositions for the treatment of HIV-infection. WO2005110411; 2005 (Tibotec Pharmaceuticals Ltd, Ire.)
   Google Scholar
• Kesteleyn BRR, Canard MFJ-MG, Van De Vreken W, Preparation of 1-phenyl-1,5-dihydropyrido[3,2-b]indol-2-ones and analogs as antiviral agents. WO2005111034; 2005 (Tibotec Pharmaceuticals Ltd, Ire.)
   Google Scholar
• Olson M, Di Grandi M, Prashad A. Preparation of 1,2-dihydroquinoline derivatives as inhibitors of RNase H and HIV reverse transcriptase. US2005203129; 2005
   Google Scholar
• Elleder D, Young JAT, Baiga TJ, Noel JP. Non-nucleoside reverse transcriptase inhibitors. WO2009061856; 2009
   Google Scholar
• Bode ML, Rousseau AL, Gravestock D, Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors. WO2010032195; 2010
   Google Scholar
• Anderson KS, Hunter R. Potent chimeric NRTI-NNRTI bifunctional inhibitors of HIV-1 reverse transcriptase. WO2009126293; 2009
   Google Scholar
• Hannongbua S. Structural information and drug–enzyme interaction of the non-nucleoside reverse transcriptase inhibitors based on computational chemistry approaches. Top Heterocycl Chem 2006;4:55-84
   Google Scholar
• Pornpan P, Punkvang A, Saparpakorn P, Recent advances in NNRTI design: computer-aided molecular design approaches. Current Computer Aided Drug Design 2009;5:174-99
   Web of Science ®Google Scholar
• Pettersson S, Clotet-Codina I, Este JA, Recent advances in combinatorial chemistry applied to development of anti-HIV drugs. Mini Rev Med Chem 2006;6(1):91-108
   PubMed Web of Science ®Google Scholar
• Wyatt PG, Bethell RC, Cammack N, Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase. J Med Chem 1995;38:1657-65
   PubMed Web of Science ®Google Scholar
• Wang Z, Wu B, Kuhen KL, Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem Lett 2006;16:4174-7
   PubMed Web of Science ®Google Scholar
• De La Rosa M, Kim HW, Gunic E, Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2006;16:4444-9
   PubMed Web of Science ®Google Scholar
• Muraglia E, Kinzel OD, Laufer R, Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant. Bioorg Med Chem Lett 2006;16:2748-52
   PubMed Web of Science ®Google Scholar
• Jiang T, Kuhen KL, Wolff K, Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I. Bioorg Med Chem Lett 2006;16:2105-8
   PubMedGoogle Scholar
• Krajewski K, Zhang Y, Parrish D, New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: synthesis, resolution, and inhibitory activity. Bioorg Med Chem Lett 2006;16:3034-8
   PubMed Web of Science ®Google Scholar
• Wu B, Kuhen K, Ngoc Nguyen T, Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1. Bioorg Med Chem Lett 2006;16:3430-3
   PubMedGoogle Scholar
• Masuda N, Yamamoto O, Fujii M, Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: design and synthesis of thiazolidenebenzenesulfonamides. Bioorg Med Chem 2004;12:6171-82
   PubMed Web of Science ®Google Scholar
• Moyle G, Boffito M, Stoehr A, Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects. Antimicrob Agents Chemother 2010;54(8):3170-8
   PubMedGoogle Scholar
• Azijn H, Tirry I, Vingerhoets J, TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010;54:718-27
   PubMed Web of Science ®Google Scholar
• Zhou XJ, Pietropaolo K, Damphousse D, Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects. Antimicrob Agents Chemother 2009;53:1739-46
   PubMed Web of Science ®Google Scholar
• Klibanov OM, Kaczor RL. IDX-899, an aryl phosphinate-indole non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection. Curr Opin Investig Drugs 2010;11:237-45
   PubMedGoogle Scholar
• Romines KR, Freeman GA, Schaller LT, Structure–activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor. J Med Chem 2006;49:727-39
   PubMed Web of Science ®Google Scholar
• Hazen RJ, Harvey RJ, St Clair MH, Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance. Antimicrob Agents Chemother 2005;49:4465-73
   PubMed Web of Science ®Google Scholar
• Ferris RG, Hazen RJ, Roberts GB, Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2005;49:4046-51
   PubMed Web of Science ®Google Scholar
• de Serres M, Moss L, Sigafoos J, The disposition and metabolism of GW695634: a non-nucleoside reverse transcriptase inhibitor (NNRTi) for treatment of HIV/AIDS. Xenobiotica 2010;40:437-45
   PubMed Web of Science ®Google Scholar
• Fatkenheuer G, Staszewski S, Plettenburg A, Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients. AIDS 2009;23:2115-22
   PubMed Web of Science ®Google Scholar
• Corbau R, Mori J, Phillips C, Lersivirine: a non-nucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus-1. Antimicrob Agents Chemother 2010;54:4451-63
   PubMed Web of Science ®Google Scholar
• Tucker TJ, Sisko JT, Tynebor RM, Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses. J Med Chem 2008;51:6503-11
   PubMed Web of Science ®Google Scholar
• Lai MT, Munshi V, Touch S, Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2009;53:2424-31
   PubMed Web of Science ®Google Scholar
• Fernandez-Romero JA, Thorn M, Turville SG, Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis 2007;34:9-14
   PubMed Web of Science ®Google Scholar
• O'Meara JA, Yoakim C, Bonneau PR, Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors. J Med Chem 2005;48:5580-8
   PubMed Web of Science ®Google Scholar
• Huang F, Koenen-Bergmann M, Macgregor TR, Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2008;52:4300-7
   PubMed Web of Science ®Google Scholar
• Patani GA, LaVoie EJ. Bioisosterism: a rational approach in drug design. Chem Rev 1996;96:3147-76
   PubMed Web of Science ®Google Scholar
• Olesen PH. The use of bioisosteric groups in lead optimization. Curr Opin Drug Discov Devel 2001;4:471-8
   PubMedGoogle Scholar
• Lima LM, Barreiro EJ. Bioisosterism: a useful strategy for molecular modification and drug design. Curr Med Chem 2005;12:23-49
   PubMed Web of Science ®Google Scholar
• Viegas-Junior C, Danuello A, da Silva Bolzani V, Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem 2007;14:1829-52
   PubMed Web of Science ®Google Scholar
• Terasaka T, Kinoshita T, Kuno M, Nakanishi I. A highly potent non-nucleoside adenosine deaminase inhibitor: efficient drug discovery by intentional lead hybridization. J Am Chem Soc 2004;126:34-5
   PubMed Web of Science ®Google Scholar
• Raju TN. The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98). Lancet 2000;355:1022
   PubMedGoogle Scholar
• Zhao H, Guo Z. Medicinal chemistry strategies in follow-on drug discovery. Drug Discov Today 2009;14:516-22
   PubMed Web of Science ®Google Scholar
• Patel Y, Gillet VJ, Bravi G, Leach AR. A comparison of the pharmacophore identification programs: catalyst, DISCO and GASP. J Comput Aided Mol Des 2002;16:653-81
   PubMed Web of Science ®Google Scholar
• Iwase K, Hirono S. Estimation of active conformations of drugs by a new molecular superposing procedure. J Comput Aided Mol Des 1999;13:499-512
   PubMed Web of Science ®Google Scholar
• Daeyaert F, de Jonge M, Heeres J, A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets. Proteins 2004;54:526-33
   PubMed Web of Science ®Google Scholar
• Daszykowski M, Walczak B, Xu QS, Classification and regression trees – studies of HIV reverse transcriptase inhibitors. J Chem Inf Comput Sci 2004;44:716-26
   PubMedGoogle Scholar
• Sluis-Cremer N, Temiz NA, Bahar I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res 2004;2:323-32
   PubMed Web of Science ®Google Scholar
• Esnouf RM, Ren J, Hopkins AL, Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc Natl Acad Sci USA 1997;94:3984-9
   PubMed Web of Science ®Google Scholar
• Duarte CD, Barreiro EJ, Fraga CA. Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem 2007;7(11):1108-19
   PubMed Web of Science ®Google Scholar
• Zhao H. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. Drug Discov Today 2007;12:149-55
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Uckun FM. Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission. Curr HIV Res 2006;4:329-45
   PubMed Web of Science ®Google Scholar
• Zhou Z, Madrid M, Evanseck JD, Madura JD. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase. J Am Chem Soc 2005;127:17253-60
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X. Designed multiple ligands: an emerging anti-HIV drug discovery paradigm. Curr Pharm Des 2009;15:1893-917
   PubMed Web of Science ®Google Scholar
• Tucker TJ, Saggar S, Sisko JT, The design and synthesis of diaryl ether second generation NNRTIs with enhanced potency versus key clinical mutations. Bioorg Med Chem Lett 2008;18:2959-66
   PubMed Web of Science ®Google Scholar
• Zhan P, Li Z, Liu X. Cosalane and its analogues: a unique class of anti-HIV agents. Mini Rev Med Chem 2010;10:966-76
   PubMed Web of Science ®Google Scholar
• Silva ATA, Castro LF, Guido RVC, Advances in prodrug design. Mini Rev Med Chem 2005;5:893-914
   PubMed Web of Science ®Google Scholar
• Ettmayer P, Amidon GL, Clement B, Testa B. Lessons learned from marketed and investigational prodrugs. J Med Chem 2004;47:2393-404
   PubMed Web of Science ®Google Scholar
• Elworthy TR, Dunn JP, Hogg JH, Orally bioavailable prodrugs of a BCS class 2 molecule, an inhibitor of HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2008;18:6344-7
   PubMed Web of Science ®Google Scholar
• Chen JM, Chen X, Kim CU, Non nucleoside reverse transcriptase inhibitors. US2006128692; 2006
   Google Scholar
• Reynolds CH, Tounge BA, Bembenek SD. Ligand binding efficiency: trends, physical basis, and implications. J Med Chem 2008;51:2432-8
   PubMed Web of Science ®Google Scholar
• Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007;6:881-90
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Sato A, el-Farrash M, S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1998;42:1340-5
   PubMed Web of Science ®Google Scholar
• Gewurz BE, Jacobs M, Proper JA, Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: a phase 1 study. J Infect Dis 2004;190:1957-61
   PubMed Web of Science ®Google Scholar
• Sato A, Hammond J, Alexander TN, In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor. Antiviral Res 2006;70:66-74
   PubMed Web of Science ®Google Scholar
• Mowbray CE, Burt C, Corbau R, Pyrazole NNRTIs 1: design and initial optimisation of a novel template. Bioorg Med Chem Lett 2009;19:5599-602
   PubMed Web of Science ®Google Scholar
• Mowbray CE, Corbau R, Hawes M, Pyrazole NNRTIs 3: optimisation of physicochemical properties. Bioorg Med Chem Lett 2009;19:5603-6
   PubMed Web of Science ®Google Scholar
• Mowbray CE, Burt C, Corbau R, Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate. Bioorg Med Chem Lett 2009;19:5857-60
   PubMed Web of Science ®Google Scholar
• Janssen PA, Lewi PJ, Arnold E, In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem 2005;48(6):1901-9
   PubMed Web of Science ®Google Scholar
• Kilby JM, Saag MS. Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection? Infect Agents Dis 1994;3:313-23
   PubMedGoogle Scholar